Twist Bioscience Corp
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
| (In thousands, except per share data) | March 31,2026 | September 30,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $122,670 | $183,049 |
| Short-term investments | 49,001 | 49,385 |
| Accounts receivable, net[1] | 64,153 | 57,019 |
| Inventories | 33,515 | 28,309 |
| Prepaid expenses and other current assets[1] | 54,100 | 15,204 |
| Total current assets | $323,439 | $332,966 |
| Property and equipment, net | 111,226 | 102,283 |
| Operating lease right-of-use assets | 70,655 | 49,377 |
| Investment in equity securities[1] | 68,087 | 54,337 |
| Goodwill | 82,195 | 82,195 |
| Intangible assets, net | 12,996 | 13,425 |
| Restricted cash, non-current | 2,182 | 2,376 |
| Other non-current assets[1] | 5,434 | 4,902 |
| Total assets | $676,214 | $641,861 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $14,682 | $11,094 |
| Accrued compensation | 27,003 | 31,288 |
| Current portion of operating lease liability | 10,443 | 13,822 |
| Accrued expenses and other current liabilities | 67,848 | 35,202 |
| Total current liabilities | $119,976 | $91,406 |
| Operating lease liability, net of current portion | 85,398 | 61,750 |
| Liability related to the sale of future revenue | 15,000 | 15,000 |
| Other non-current liabilities[1] | 746 | 747 |
| Total liabilities | $221,120 | $168,903 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value —200,000 and 200,000 shares authorized at March 31, 2026 and September 30, 2025, respectively; 62,154 and 60,632 shares issued and outstanding at March 31, 2026 and September 30, 2025, respectively | $1 | $— |
| Additional paid-in capital | 1,849,838 | 1,793,163 |
| Accumulated other comprehensive loss | (639) | (627) |
| Accumulated deficit | (1,394,106) | (1,319,578) |
| Total stockholders’ equity | $455,094 | $472,958 |
| Total liabilities and stockholders’ equity | $676,214 | $641,861 |
[1] Includes related party balances, see Note 12 - Related Party Transactions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.